A Phase 2 interventional study of BR55 in Ovarian Cancer, sponsored by Bracco Diagnostics, Inc. Terminated at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Bracco Diagnostics, Inc (part of Bracco) · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,780 studies in Ovarian Neoplasms with a site in United States — 277 open to participants now, 453 under way, 46 of them phase 3. Ovarian Neoplasms · United States.
Among the 1,780 studies in Ovarian Neoplasms with a site in United States, this one is the 1,245th largest by enrollment of the 1,499 interventional ones that give a count, is one of 76 that started in 2018, is one of 485 in phase 2, and was the 1,111th registered.
3,389 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →277 of the 1,780 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Michael J. Goodheart · Sites in United States
Ages 18–99 · Women only
Crescent Biopharma, Inc. · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, China, Israel and 2 more countries
Ages 18+ · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18+
GE Healthcare · Sites in United States, Sweden
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,780 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 770 · Phase 2 718 · Phase 3 114 · Phase 4 8
First in 1980; this study’s year is marked. 76 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 54 across 2,555 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 47 across the 1,499 interventional studies, 176 across the 195 observational. Of the 1,211 that completed or were terminated, 445 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
714 of 1,780 have an industry lead sponsor. The 10 most frequent:
This study is registered under Bracco Diagnostics, Inc, one of the names counted as Bracco. Under that name alone:
Bracco Diagnostics, Inc is the lead sponsor of 49 studies on the registry; 1 is open to participants now.
Bracco has 2 studies filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
160 of the studies in Ovarian Neoplasms with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05281471Phase 3Genelux CorporationEfficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | 2026-12 |
| NCT04498117Phase 3CanariaBio Inc.Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | 2026-12-26 |
| NCT05059522Phase 3PfizerContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | 2026-12-31 |
| NCT04095364Phase 3NRG OncologyLetrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | 2027-02-01 |
Add all 160 to your calendar (.ics) → With an account.
Among the 1,780 studies in Ovarian Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an exploratory phase II, single center, open label, prospective study of BR55 CEUS for characterization of ovarian lesions in subjects with suspected ovarian cancer.
A total of sixty (60) subjects scheduled to undergo salpingo-oophorectomy within 30 days of BR55 CEUS examination will be enrolled to obtain approximately 30 subjects with benign ovarian lesions and 30 with malignant ovarian lesions based on the truth standard (TS).
The first 10 subjects will receive BR55 at a dose of 0.03 mL/kg. Assuming these first 10 subjects will show technically adequate images, subsequent subjects enrolled in the study will continue to receive 0.03 mL/kg dose of BR55; otherwise, subjects will be switched to a 0.05 mL/kg dose of BR55.
The final cancer diagnosis will be obtained for all subjects by histopathology.
Inclusion Criteria: Enroll a subject if he/she meets the following inclusion criteria:
Exclusion Criteria: Exclude a subject if the subject does not fulfill the inclusion criteria, or if any of the following conditions are observed:
Is a pregnant or lactating female. Exclude the possibility of pregnancy:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive a single dose of BR55 at 0.03 mL/kg or 0.05 mL/kg.
Drug: BR55
A novel targeted ultrasound contrast agent
Visual Assessment of BR55 Enhancement
BR55-enhanced images will be visually assessed using a 3-point scale (no enhancement=no focal targeted, stationary imaging signal was detectable; weak enhancement=weak focal targeted imaging signal was detectable and considered possibly stationary; strong enhancement=well-defined and strong focal targeted imaging signal was detectable and considered as definitely stationary).
Time frame: 30 minutes post-dose on Day 1
Adverse Events
Number of participants who received the contrast agent and experienced an adverse event.
Time frame: 2 days (day of and 24 hours after BR55 administration)
A total of 60 subjects scheduled to undergo salpingo-oophorectomy within 30 days of BR55 contrast-enhanced ultrasound (CEUS) examination were to be enrolled to obtain approx. 30 subjects with benign ovarian lesions and 30 with malignant ovarian lesions based on the Truth Standard (TS; histopathology). This study was terminated early due to expiration of available BR55, therefore, only 14 of the 60 anticipated participants in the study were enrolled.
| Milestone | Treatment |
|---|---|
| Started | 14 |
| Completed | 13 |
| Not completed | 1 |
| Withdrew: Surgery not performed | 1 |
BR55-enhanced images will be visually assessed using a 3-point scale (no enhancement=no focal targeted, stationary imaging signal was detectable; weak enhancement=weak focal targeted imaging signal was detectable and considered possibly stationary; strong enhancement=well-defined and strong focal targeted imaging signal was detectable and considered as definitely stationary).
| Participants | Treatment |
|---|---|
| No enhancement | 5 |
| Weak enhancement | 6 |
| Strong enhancement | 3 |
Number of participants who received the contrast agent and experienced an adverse event.
| Participants | Treatment |
|---|---|
| Adverse Events | 3 |
Collected over Safety monitoring began at the time of signing Informed Consent and continued for 24 hours after BR55 administration, up to 3 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment | 0/14 (0%) | 0/14 (0%) | 3/14 (21.4%) |
| Event | Treatment |
|---|---|
| HeadacheNervous system disorders | 3/14 |
| ItchinessGeneral disorders | 1/14 |
All participants enrolled and dosed in the study who provided demographic information.
| Age, Categorical(Participants) | Treatment |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 10 |
| >=65 years | 4 |
| Age, Continuous(years) | Treatment |
|---|---|
| Mean | 55.4 (28 to 76) |
| Sex: Female, Male(Participants) | Treatment |
|---|---|
| Female | 14 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | Treatment |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 12 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Treatment |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 4 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 10 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Treatment |
|---|---|
| United States | 14 |
| Exposure to Investigational Product(Actual Volume Administered (mL)) | Treatment |
|---|---|
| Mean | 2.16 ± 0.246 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2018 to primary completion in Apr 2021, 28 months.
Results were first posted in Sep 2024, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BR55